Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer

Abstract

BACKGROUND: We conducted a Phase 1 study to evaluate safety and activity of olaparib tablets and oral cyclophosphamide. METHODS: Patients had metastatic breast cancer (BC) or recurrent high-grade serous ovarian cancer (HGSOC), performance status 0-2, and ≤3 lines of prior therapy. Patients were treated using a dose escalation strategy with cohort expansion once maximal tolerated dose (MTD) was determined. Dose level 1 (DL1): olaparib 300 mg bid, cyclophosphamide 50 mg on days 1, 3, and 5, weekly. DL2: olaparib 300 mg bid, cyclophosphamide 50 mg, days 1-5 weekly. RESULTS: Of 32 patients, 23 had HGSOC (germline BRCA mutation [gBRCAm] 70%) and 9 had BC (gBRCAm 67%). Four were treated at DL1 and 28 at DL2, the MTD. Haematological adverse events (AEs) were most common: grade 3/4 AEs: lymphopenia 75%, anaemia 31%, neutropenia 37%, thrombocytopenia 47%. Two permanently discontinued treatment due to haematological AEs. In BC, no objective response was reported. Unconfirmed objective response was 48% and 64% for all HGSOC and gBRCAm subset, respectively. CA125 responses were 70% (all HGSOC) and 92% (gBRCAm). CONCLUSIONS: In HGSOC and BC, olaparib 300 mg bid and cyclophosphamide 50 mg on days 1-5 weekly were tolerable and active, particularly in gBRCAm, and is worthy of further investigation.

The role of double‐strand break repair, translesion synthesis, and interstrand crosslinks in colorectal cancer progression—clinicopathological data and survival

“…Contribution of aberrant DNA repair and DNA damage response in carcinogenesis and its response to treatments has been well established. Furthermore, the study of DNA repair components as oncological molecular markers has already reached clinical practice, including MGMT promoter methylation status (glioblastoma), BRCA1/2 mutations (breast and ovarian cancer), and MMR deficiency (colorectal, endometrial, ovarian, and other cancer types) …”

Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

“…Early-phase clinical trials of olaparib demonstrated activity signals in patients with OC, with favorable tolerance and response rates. 58 , 111 – 113 Following these promising results, 114 a notable randomized placebo-controlled phase II trial, Study 19 (NCT00753545), evaluated olaparib as maintenance monotherapy for patients with platinum-sensitive recurrent OC. The median PFS was significantly longer in the olaparib arm compared with placebo (3.6 months longer, P < 0.001).…”

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers

“…Ultimately, cancer cell death is the goal of PARPi treatment, and thus BRCA1/2 deficient patients have been the primary target population for treatment with this class of drugs. PARPi also shows promises in treating carriers of a PALB2 mutation, and has been tested with some success on triple-negative breast cancers, serous carcinomas of the ovaries, tumors with high replicative stress levels, and in combination with immune checkpoint blockade [62] , [63] , [64] , [65] , [66] . This cautiously offers hope for the development of novel combination therapies.…”